XML 47 R18.htm IDEA: XBRL DOCUMENT v3.2.0.727
Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Mar. 31, 2015
Accounting Policies [Abstract]  
Schedule of Fixed Assets

Fixed assets consist of the following:

 

     Estimated
Useful Lives in years		    June 30,      March 31,  
        2014      2013      2015  
                        (unaudited)  

Lab equipment

    3 - 5      90,000         81,000         90,000   

Less accumulated depreciation

         (33,000 )       (6,000 )       (53,000 ) 
     

 

 

     

 

 

     

 

 

  

Fixed assets, net

 $ 57,000    $ 75,000    $ 37,000   
     

 

 

     

 

 

     

 

 

  

Aytu recorded the following depreciation expense in the respective periods:

 

     Year Ended June 30,      March 31,
2015		  
     2014      2013     
                   (unaudited)  

Depreciation expense

    $ 27,000       $ 6,000       $ 20,000   
Schedule of Patents

Patents consist of the following:

 

     June 30,      March 31,
2015		  
     2014      2013     
                   (unaudited)  

Patents

    $ 880,000       $ 880,000       $ 880,000   

Less accumulated armortization

      (180,000 )       (110,000 )       (234,000 ) 
  

 

 

     

 

 

     

 

 

  

Patents, net

 $ 700,000    $ 770,000    $ 646,000   
  

 

 

     

 

 

     

 

 

  
Schedule of Amortization Expense

Aytu recorded the following amortization expense in the respective periods:

 

     Year Ended June 30,      Nine Months Ended  
     2014      2013      March 31, 2015  
                   (unaudited)  

Amortization expense

    $ 70,000       $ 53,000       $ 54,000   
Schedule of Future Amortization Expense

Future amortization from the nine months ended March 31, 2015 is as follows:

 

2015

    $ 18,000   

2016

      71,000   

2017

      71,000   

2018

      71,000   

2019

      71,000   

Thereafter

      344,000   
  

 

 

  
$ 646,000   
  

 

 

  
Schedule of Research and Development Expense

Research and development costs are expensed as incurred with expenses recorded in the respective periods as follows:

 

     Year Ended June 30,      March 31,
2015		  
     2014      2013     
                   (unaudited)  

Research and development costs

    $ 4,059,000       $ 2,756,000       $ 2,574,000